about
C/EBPα Dysregulation in AML and ALLESE-1 is a novel transcriptional mediator of angiopoietin-1 expression in the setting of inflammationIsoform-specific potentiation of stem and progenitor cell engraftment by AML1/RUNX1t(8;21)(q22;q22) Fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression.AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutationsDichotomy of AML1-ETO functions: growth arrest versus block of differentiationAcute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profilesAltered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network.Phosphorylation of RUNX1 by cyclin-dependent kinase reduces direct interaction with HDAC1 and HDAC3.Genetic profile of acute myeloid leukemia.Runx1 deletion or dominant inhibition reduces Cebpa transcription via conserved promoter and distal enhancer sites to favor monopoiesis over granulopoiesis.Molecular genetic analysis of haematological malignancies: I. Acute leukaemias and myeloproliferative disorders.Cyclin-dependent kinase phosphorylation of RUNX1/AML1 on 3 sites increases transactivation potency and stimulates cell proliferation.Runx1 Phosphorylation by Src Increases Trans-activation via Augmented Stability, Reduced Histone Deacetylase (HDAC) Binding, and Increased DNA Affinity, and Activated Runx1 Favors GranulopoiesisCell cycle and developmental control of hematopoiesis by Runx1.Novel targeted drug therapies for the treatment of childhood acute leukemiaC/EBPα in normal and malignant myelopoiesis.Multimerization via its myosin domain facilitates nuclear localization and inhibition of core binding factor (CBF) activities by the CBFbeta-smooth muscle myosin heavy chain myeloid leukemia oncoprotein.ETV6/RUNX1 abrogates mitotic checkpoint function and targets its key player MAD2L1.AML1/RUNX1 increases during G1 to S cell cycle progression independent of cytokine-dependent phosphorylation and induces cyclin D3 gene expression.Polyomavirus enhancer-binding protein 2/core binding factor/acute myeloid leukemia factors contribute to the cell type-specific activity of the CD11a integrin gene promoter.
P2860
Q22065117-4E3108B7-5419-4C8A-B150-797673FAA5C8Q24304282-20892661-1A6B-4F88-B5AA-B283F227CF74Q27307661-9E8BD8BF-B27C-44D7-9AE2-65646030119FQ33338784-EDA4584A-823D-45ED-A4E5-54499275B25BQ33943238-31536A91-602E-4013-AF71-B37DA86966BBQ33969245-7B3CFCE8-3E84-4C94-9D54-A3B181621CB9Q34098676-DF8F9486-AFA3-408B-A8FD-623CDED8920BQ34372000-D2D8175E-D14C-417E-B1BB-E21AF6F65444Q34452491-D61C0ACF-FDD9-43FC-B245-DEC9CDCDE6E6Q34680927-771C9452-70BE-4E4B-BC68-53DD924F8E5CQ35995201-B9EF9443-D079-4F7B-A954-017A11794EE5Q36153422-89DB62B2-960E-47E4-84D7-0CD63F170B3CQ36407144-ABE25900-9B5F-4D97-B058-D7710A70C414Q36442414-23B26572-57AA-4508-AFF3-0477DA49477DQ36543603-1323F5F0-BDF2-4417-A38D-DC1C3EED0AFBQ37477482-D4711C01-45C8-46AB-994E-34946BA98861Q38370875-81ED0029-6132-45C4-9EA4-8B13BAB7550EQ39675523-BA9293E3-E1F1-4585-80A7-3113C3582B27Q39733962-7F9601C1-3E47-4FBE-9620-BE3186042929Q40595051-D6D82444-EEE9-4A72-81ED-9418F08D5EFDQ40869712-31ACEA1B-113A-47AA-9E02-AFAD565248B5
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Leukemogenesis by CBF oncoproteins.
@ast
Leukemogenesis by CBF oncoproteins.
@en
type
label
Leukemogenesis by CBF oncoproteins.
@ast
Leukemogenesis by CBF oncoproteins.
@en
prefLabel
Leukemogenesis by CBF oncoproteins.
@ast
Leukemogenesis by CBF oncoproteins.
@en
P356
P1433
P1476
Leukemogenesis by CBF oncoproteins.
@en
P2093
Friedman AD
P2888
P304
P356
10.1038/SJ/LEU/2401590
P577
1999-12-01T00:00:00Z
P6179
1056650562